These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22773165)

  • 21. Striatal and extrastriatal dopamine D₂ receptor occupancy by the partial agonist antipsychotic drug aripiprazole in the human brain: a positron emission tomography study with [¹¹C]raclopride and [¹¹C]FLB457.
    Takahata K; Ito H; Takano H; Arakawa R; Fujiwara H; Kimura Y; Kodaka F; Sasaki T; Nogami T; Suzuki M; Nagashima T; Shimada H; Kato M; Mimura M; Suhara T
    Psychopharmacology (Berl); 2012 Jul; 222(1):165-72. PubMed ID: 22237854
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Koole M; Schmidt ME; Hijzen A; Ravenstijn P; Vandermeulen C; Van Weehaeghe D; Serdons K; Celen S; Bormans G; Ceusters M; Zhang W; Van Nueten L; Kolb H; de Hoon J; Van Laere K
    J Nucl Med; 2019 May; 60(5):683-690. PubMed ID: 30262518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacology of JNJ-37822681, a specific and fast-dissociating D2 antagonist for the treatment of schizophrenia.
    Langlois X; Megens A; Lavreysen H; Atack J; Cik M; te Riele P; Peeters L; Wouters R; Vermeire J; Hendrickx H; Macdonald G; De Bruyn M
    J Pharmacol Exp Ther; 2012 Jul; 342(1):91-105. PubMed ID: 22490380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
    Kapur S; Zipursky R; Jones C; Shammi CS; Remington G; Seeman P
    Arch Gen Psychiatry; 2000 Jun; 57(6):553-9. PubMed ID: 10839333
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Active cyamemazine metabolites in patients treated with cyamemazine (Tercian®): influence on cerebral dopamine D2 and serotonin 5-HT (2A) receptor occupancy as measured by positron emission tomography (PET).
    Hodé Y; Benyamina A; Arbus C; Reimold M
    Psychopharmacology (Berl); 2011 Oct; 217(3):315-21. PubMed ID: 21479533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An open-label, positron emission tomography study of the striatal D
    Wong DF; Raoufinia A; Bricmont P; Brašić JR; McQuade RD; Forbes RA; Kikuchi T; Kuwabara H
    Eur J Clin Pharmacol; 2021 May; 77(5):717-725. PubMed ID: 33196868
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
    Mamo D; Graff A; Mizrahi R; Shammi CM; Romeyer F; Kapur S
    Am J Psychiatry; 2007 Sep; 164(9):1411-7. PubMed ID: 17728427
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride.
    Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF
    Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential responses to JNJ-37822681, a specific and fast dissociating dopamine D2 receptor antagonist, in cynomolgus monkey and Sprague-Dawley rat general toxicology studies: clinical observations, prolactin levels, mammary histopathology findings and toxicokinetics.
    de Waal EJ; Desmidt M; Korte S; Niehoff M; Chase K; Arrowsmith W; Lampo A
    J Appl Toxicol; 2014 Sep; 34(9):974-92. PubMed ID: 24105799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride.
    Kegeles LS; Slifstein M; Frankle WG; Xu X; Hackett E; Bae SA; Gonzales R; Kim JH; Alvarez B; Gil R; Laruelle M; Abi-Dargham A
    Neuropsychopharmacology; 2008 Dec; 33(13):3111-25. PubMed ID: 18418366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antipsychotic-associated mental side effects and their relationship to dopamine D2 receptor occupancy in striatal subdivisions: a high-resolution PET study with [11C]raclopride.
    Kim JH; Son YD; Kim HK; Lee SY; Cho SE; Kim YB; Cho ZH
    J Clin Psychopharmacol; 2011 Aug; 31(4):507-11. PubMed ID: 21694619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. D2 receptor occupancy in conscious rat brain is not significantly distinguished with [3H]-MNPA, [3H]-(+)-PHNO, and [3H]-raclopride.
    Peng T; Zysk J; Dorff P; Elmore CS; Ström P; Malmquist J; Ding M; Tuke D; Werkheiser J; Widzowski D; Mrzljak L; Maier D
    Synapse; 2010 Aug; 64(8):624-33. PubMed ID: 20340171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determination of dopamine D₂ receptor occupancy by lurasidone using positron emission tomography in healthy male subjects.
    Wong DF; Kuwabara H; Brašić JR; Stock T; Maini A; Gean EG; Loebel A
    Psychopharmacology (Berl); 2013 Sep; 229(2):245-52. PubMed ID: 23649882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia.
    Gefvert O; Eriksson B; Persson P; Helldin L; Björner A; Mannaert E; Remmerie B; Eerdekens M; Nyberg S
    Int J Neuropsychopharmacol; 2005 Mar; 8(1):27-36. PubMed ID: 15710053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.
    Olsen CK; Brennum LT; Kreilgaard M
    Eur J Pharmacol; 2008 Apr; 584(2-3):318-27. PubMed ID: 18325493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [(11) C]-(+)-PHNO and [(11) C]raclopride positron emission tomography imaging study.
    Abi-Jaoude E; Segura B; Obeso I; Cho SS; Houle S; Lang AE; Rusjan P; Sandor P; Strafella AP
    Hum Brain Mapp; 2015 Jul; 36(7):2592-601. PubMed ID: 25788222
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of D₂ dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects.
    Nord M; Nyberg S; Brogren J; Jucaite A; Halldin C; Farde L
    Int J Neuropsychopharmacol; 2011 Nov; 14(10):1357-66. PubMed ID: 21477416
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brain region binding of the D2/3 agonist [11C]-(+)-PHNO and the D2/3 antagonist [11C]raclopride in healthy humans.
    Graff-Guerrero A; Willeit M; Ginovart N; Mamo D; Mizrahi R; Rusjan P; Vitcu I; Seeman P; Wilson AA; Kapur S
    Hum Brain Mapp; 2008 Apr; 29(4):400-10. PubMed ID: 17497628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia.
    Mamo D; Kapur S; Keshavan M; Laruelle M; Taylor CC; Kothare PA; Barsoum P; McDonnell D
    Neuropsychopharmacology; 2008 Jan; 33(2):298-304. PubMed ID: 17443131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO.
    Graff-Guerrero A; Mamo D; Shammi CM; Mizrahi R; Marcon H; Barsoum P; Rusjan P; Houle S; Wilson AA; Kapur S
    Arch Gen Psychiatry; 2009 Jun; 66(6):606-15. PubMed ID: 19487625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.